BloodCellsByAlexia

TMLI 12Gy is better tolerated than FluMel140, can be done outpatient. #Tandem26 #Leusm #BMTsm

Important conclusions were drawn from this study: 1. There's a gigantic room for improvement in outcome definition, selection, and implementation in ITP clinical trials 2. Friendship and brightly kind mentorship are a great motor for science Happy for this incredible humans

Teclistamab doses can be reduced by half, given for a limited time, and remain highly effective for RR MM patients maximizing access. Look for the TECLISito poster on Sunday at #ASH25 #Shouldvebeenoral #MMsm @rennquevedo @dgomezalmaguer

Be on the lookout for the work of our trainees and faculty at #ASH25 @uanl a couple of orals and many posters focused on access, practical implementation and global hematology. From Monterrey 🇲🇽 to Orlando 🍊see you 🔜

@morcossandino @barbie_context Identificada al 100, hahahahaha

@barbie_context @BloodCellsByAle

@morcossandino @GomezDLeonMD @MDPIOpenAccess Los invito a leer este interesante review, un análisis profundo sobre los desafíos y oportunidades en el tratamiento de la leucemia mieloide aguda en contextos con acceso limitado a recursos. ¡Muchas felicidades al equipo por este gran trabajo! #Hematología #LMA

🧵 1/9 📢 Just published! "Advances in the Treatment of AML: Implications for Low- and Middle-Income Countries" 🔓 Open access: mdpi.com/2227-9059/13/5… 🧬 This thread breaks down key insights—and how they can help improve AML care in resource-limited settings.

@morcossandino @GomezDLeonMD @MDPIOpenAccess Los invito a leer este interesante review, un análisis profundo sobre los desafíos y oportunidades en el tratamiento de la leucemia mieloide aguda en contextos con acceso limitado a recursos. ¡Muchas felicidades al equipo por este gran trabajo! #Hematología #LMA

ALL management @ MD Anderson 2025 🔬 Subtype & age-driven 🧬 Ph+ B-ALL: TKI ➕ Chemo/Blina → TKI maintenance 🧪 Ph- B-ALL: HCVAD ➕ Blina ± InO 🧱 T-ALL: HCVAD ➕ Nelarabine ± Venetoclax ⚡ Burkitt: R-hyperCVAD / DA-R-EPOCH 🧫 MRD (NGS) ➡️ guides SCT #ALL #Leukemia #Hematology

🌟 ANA for diagnosis of connective tissue diseases

🔬Castleman Disease:A spectrum of lymphoproliferative disorders with systemic inflammation🌡️& lymphadenopathy ✨Types: 1️⃣Unicentric (UCD):Localized lymph node📌,>95% survival 2️⃣Multicentric (MCD): Generalized, HHV8+ or Idiopathic 💡iMCD treatment: ✅Steroids ✅Anti-IL6 Siltuximab

Missing San Diego? Read our wrap-up piece for ASH Daily News where @morcossandino and me awarded "Golden Globules" to clinically relevant and widely applicable findings from oral abstracts presented at #ASH24... Written after watching Gladiator II ⚔️🛡️ tinyurl.com/4wumuzka

@Itsinmyblood92 🫰🏻❤️

Alexia is not only a wonderful human being but also a brilliant hematologist with so much to offer. Her insights and dedication are paving the way for incredible advancements in science and patient care. A true inspiration! #ASH24 @BloodCellsByAle 🩸

Honored to receive the David M. Goldenberg CRTI Abstract Award. Grateful to my mentor @GomezDLeonMD Your dedication and invaluable lessons have been a constant source of inspiration and growth. @ASH_hematology #ASH24

Get a glimpse of what’s ahead at the 10 #ScientificWorkShops: Impossible to Resist 💪🏻🧬 at #ASH24 ➡️ ashpublications.org/ashnewsdaily/n… #Hematology #immunonc #geriheme #TcellRX #MEDTwitter #ASHNewsDaily @ASH_hematology @GomezDLeonMD @JuliPerezBot

The peripheral blood smear leads to diagnosis in patient with undifferentiated shock, emphasizing its importance in the hematologist's toolkit. doi.org/10.1002/ajh.27… #hematology #heme #hemepath @The_heme_story @BloodClotDoc

This case highlights the critical role of immunosuppressive therapy, especially in resource-limited settings where newer treatments like caplacizumab aren't readily available. @BloodCellsByAle @paulo_ug #Hematology #TTP #GlobalHealth 🩸🩸